1. Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B
- Author
-
Beatriz Mateos-Muñoz, María Buti, Inmaculada Fernández Vázquez, Marta Hernández Conde, Vanesa Bernal-Monterde, Fernando Díaz-Fontenla, Rosa María Morillas, Luisa García-Buey, Ester Badía, Mireia Miquel, Alberto Amador-Navarrete, Sergio Rodríguez-Tajes, Lucía Ramos-Merino, Antonio Madejón, Montserrat García-Retortillo, Juan Ignacio Arenas, Joaquín Cabezas, Jesús Manuel González Santiago, Conrado Fernández-Rodríguez, Patricia Cordero, Moisés Diago, Antonio Mancebo, Alberto Pardo, Manuel Rodríguez, Elena Hoyas, Jose Javier Moreno, Juan Turnes, Miguel Ángel Simón, Cristina Marcos-Fosch, Jose Luis Calleja, Rafael Bañares, Sabela Lens, Javier Garcia-Samaniego, Javier Crespo, Manuel Romero-Gomez, Francisco Gea, Enrique Rodríguez de Santiago, Santiago Moreno, Agustin Albillos, Institut Català de la Salut, [Mateos-Muñoz B] Hospital Universitario Ramón y Cajal, CIBEREHD, IRYCIS, Universidad de Alcalá, Madrid, Spain. [Buti M, Marcos-Fosch C] Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBEREHD, Barcelona, Spain. [Fernández Vázquez I] Gastroenterology Department, Hospital Universitario, 12 de Octubre, Madrid, Spain. [Hernández Conde M] Gastroenterology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain. [Bernal-Monterde V] Gastroenterology Department, Hospital Miguel Servet, Zaragoza, Spain. [Díaz-Fontenla F] Gastroenterology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Otros calificadores::/uso terapéutico [Otros calificadores] ,Physiology ,Gastroenterology ,Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] ,Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] ,Other subheadings::Other subheadings::/drug therapy [Other subheadings] ,virosis::infecciones por virus ADN::infecciones por Hepadnaviridae::hepatitis B::hepatitis B crónica [ENFERMEDADES] ,Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents [CHEMICALS AND DRUGS] ,COVID-19 (Malaltia) - Tractament ,acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos [COMPUESTOS QUÍMICOS Y DROGAS] ,virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] ,Medicaments antivírics - Ús terapèutic ,Other subheadings::/therapeutic use [Other subheadings] ,Hepatitis B - Tractament ,Virus Diseases::DNA Virus Infections::Hepadnaviridae Infections::Hepatitis B::Hepatitis B, Chronic [DISEASES] - Abstract
COVID-19; Hepatitis B; Tenofovir COVID-19; Hepatitis B; Tenofovir COVID-19; Hepatitis B; Tenofovir Background and Aims HIV-positive patients on tenofovir hydroxyl fumarate (TDF)/emtricitabine have a lower risk of COVID-19 and hospitalization than those given other treatments. Our aim was to analyze the severity of COVID-19 in patients with chronic hepatitis B (CHB) on TDF or entecavir (ETV). Methods Spanish hospital databases (n = 28) including information regarding adult CHB patients on TDF or ETV for the period February 1st to November 30th 2020 were searched for COVID-19, defined as a positive SARS-CoV-2 polymerase chain reaction, and for severe COVID-19. Results Of 4736 patients, 117 had COVID-19 (2.5%), 67 on TDF and 50 on ETV. Compared to patients on TDF, those on ETV showed (p
- Published
- 2023
- Full Text
- View/download PDF